Dr. Patrick Huddie
Dr. Patrick Huddie, a partner of Westbury Group, is an experienced investment banker with substantial experience in advising entrepreneurial ventures in the healthcare sector. In the course of his career, he has advised many companies regarding mergers and acquisitions, as well as debt and equity financings. His clients have been primarily in the healthcare sector, including biotechnology, consumer goods, diagnostics, and medical devices. Previously Huddie founded and operated an electro-optical engineering services company that provided imaging and laser technology to federal government clients, as well as to biomedical research organizations and to the microelectronics industry. The company successfully licensed and implemented NASA technology to create compact ultraviolet lasers for terrestrial applications.
John Jensen is a Managing Director of Westbury Group, an investment bank that focuses on broad advisory and execution services for middle-market companies. With more than forty years of investment banking experience, Jensen spent thirty-two years at Merrill Lynch, retiring as the Vice Chairman of Global Equity Capital Markets. In his career, he led the fundraising of more than $100 billion in equity offerings, including large, complex, global privatizations, such as France Telecom. After retiring from Merrill Lynch, Jensen founded a healthcare technology company, which was sold to a publicly held Belgian company in 2012. Jensen graduated from the University of North Carolina at Chapel Hill with a B.A. with Honors and he attended the New York University, Stern School of Business.
Cynthia Ekberg Tsai
Ms. Tsai comes to Bioxytran with more than 30 years of experience in global biotechnology and medical technologies. Ms. Tsai spent 16 years on Wall Street as a Vice President with Merrill Lynch and Kidder Peabody. She currently is CEO of Tana Systems, a global software and IT company based in the U.S. and India. Ms. Tsai is the former Founder and CEO of HealthExpo, the largest consumer healthcare event in the US, where she grew the enterprise from concept to execution, attracting more than 50 million consumers to HealthExpo. Previously, Ms. Tsai was a General Partner in MassTech Ventures, a multi-million-dollar equity fund focused on technology development at Massachusetts Institute of Technology. Ms. Tsai currently serves on the Board of Selectors for the Jefferson Foundation Awards and is on the board of the Prix Galien Foundation. In 1999, the Harvard Business School Alumni Chapter in New York recognized Ms. Tsai with an Early Stage Honor Roll Award for Entrepreneurship. In 2004, she also received a “Leading Woman Entrepreneur of the World” Award from the Star Foundation in Overland Park, Kansas. She earned a B.A. in Psychology from the University of Missouri.
Mr. Barkman has over 25 years of experience in the finance industry. This experience started with his initial days as a financial analyst and trader which lead to his leadership role as First Vice President of Janney Montgomery Scott. LLC and as Founder and CEO of Riverview Capital Enterprises LLC. Mr. Barkman became a trusted advisor to not only his individual clients but many small and micro-cap companies such as Bioxytran.
Steve Aust played Division 1 collegiate basketball for Pepperdine University and brings a passion for sports, competition, and leadership to all of his business pursuits. He has owned and operated direct sales and marketing companies in the nutritional, cosmetic, travel and entertainment businesses, was ranked as a top 100 Networkers for 12 years, built networks international distributors and is a former investment banker. Steve has firsthand experience of a loved one suffering through a stroke. He understood our value proposition immediately – buying stroke victims critical extra hours so that they can be treated before irreversible brain damage occurs. Mr. Aust is currently President of VRDT Corporation; and will provide strategic planning to building awareness of Bioxytran’s technology with key opinion leaders.
Dr. Juan Carlos Lopez-Telavera
Medical Advisory Board
Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, as Vice President and Global Development Lead, and Roche Laboratories as Senior Medical Director. Before moving into the industry, Dr. Lopez-Talavera was an Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center, Associate Professor of Medicine with the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.
Medical Advisory Board
Dr. Chen-Walden has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. She has thirty years of regulatory experience in EMEA and in individual European countries. Since 2004, She has consulted for the European Clinical and Regulatory Consultancy in medical monitoring, quality assurance, and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases, and medical devices. From 2000 to 2003, Dr. Chen-Walden was Director of International Regulatory Affairs, Covalent Group Ltd. From 1997 to 2000, she was Medical, Drug Safety, and Regulatory Director at CRC, a clinical contract research organization in France. Dr. Chen-Walden received her MD degree from the University of Tel Aviv, Israel. She has practiced medicine in Germany and France.
Prof. Avraham Mayevsky
Scientific Advisory Board
Prof. Avraham Mayevsky is a worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology. Prof. Mayevsky is a professor at the Faculty of Life Sciences, Bar-Ilan University, Israel. He founded Vital Medical Ltd. He served as Head of the Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar-Ilan University, where he established a center of tissue physiology. He served as Visiting professor at University of Pennsylvania and Johns Hopkins Medical School World-recognized expert in tissue physiology, especially in brain metabolism. He Published over 150 papers and patents. He has published over 170 papers in scientific journals and is the author of five patents. Prof. Mayevsky completed PhD from Weizmann Institute of Science, Rehovot, Israel.